NEORX BEGINS TRIAL OF PICOPLATIN

NeoRx has treated the first patient in a Phase I/II clinical trial of its lead product, picoplatin, for the potential front-line treatment of colorectal cancer.

Picoplatin is a new generation platinum therapy that provides a differentiated spectrum of activity, reduced reactivity and an improved safety profile. An intravenous chemotherapeutic agent, picoplatin is designed to overcome platinum resistance associated with the treatment of solid tumors. In addition to the colorectal cancer trial, picoplatin is being studied in an open-label, multicenter Phase II clinical trial in small cell lung cancer patients.